Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 33

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 33
---
 of our Common Stock available
for future issuance by the amount of the reduction effected by the Reverse Stock Split.

| 19 |

Following the Reverse Stock Split, the
Board will have the authority, subject to applicable securities laws, to issue all authorized and unissued shares without further stockholder
approval, upon such terms and conditions as the Board deems appropriate. Although we consider financing opportunities from time to time,
we do not currently have any plans, proposals, or understandings to issue the additional shares that would be available if the
Reverse Stock Split is approved and effected, but some of the additional shares underlie warrants which could be exercised after the
Reverse Stock Split is effected.

Effects of the Reverse Stock Split

Management does not anticipate that our
financial condition, the percentage ownership of Common Stock by management, the number of our stockholders, or any aspect of
our business will materially change as a result of the Reverse Stock Split. Because the Reverse Stock Split will apply to all issued
and outstanding shares of Common Stock and outstanding rights to purchase Common Stock, the proposed Reverse Stock Split will
not alter the relative rights and preferences of existing stockholders, except to the extent the Reverse Stock Split will result in fractional
shares, as discussed in more detail below.

The Common Stock is currently registered
under Section 12(b) of the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The
Reverse Stock Split will not affect the registration of the Common Stock under the Exchange Act or the listing of the Common Stock on
Nasdaq Capital Market (other than to the extent it facilitates compliance with Nasdaq Capital Market continued listing standards). Following
the Reverse Stock Split, the Common Stock will continue to be listed on the Nasdaq Capital Market, although it will be considered a new
listing with a new Committee on Uniform Securities Identification Procedures (“CUSIP”) number.

The rights of the holders of the Common Stock will
not be affected by the Reverse Stock Split, other than as a result of the treatment of fractional shares as described below. For example,
a holder of 2% of the voting power of the outstanding shares of the Common Stock immediately prior to the effectiveness of the Reverse
Stock Split will generally continue to hold 2% of the voting power of the outstanding shares of the Common Stock immediately after effecting
the Reverse Stock Split. The number of stockholders of record will not be affected by the Reverse Stock Split (except to the extent any
are cashed out as a